ADARx Pharmaceuticals, Inc. ADRX
NasdaqGS
$18.60-0.95 (-4.84%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
These ratios divide the lines in the statements below by the current price; both inputs of every value are visible on this page. The P/E on the overview comes from the same calculation. P/E and P/S are left blank for loss-making companies or where revenue is not reported. Not investment advice.
| LTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | $6.13M | $3.45M | $0 |
| Revenue growth (YoY) | — | — | — |
| Operating expenses | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating Income | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating margin | MakklerPRO | MakklerPRO | MakklerPRO |
| EBITDA | MakklerPRO | MakklerPRO | MakklerPRO |
| Pre-tax income | MakklerPRO | MakklerPRO | MakklerPRO |
| Net Income | -$87.87M | -$73.09M | -$46.36M |
| Net margin | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted EPS | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted shares | MakklerPRO | MakklerPRO | MakklerPRO |
| LTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & equivalents | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Current Assets | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Assets | $456.33M | $507.66M | $233.45M |
| Total Current Liabilities | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Liabilities | MakklerPRO | MakklerPRO | MakklerPRO |
| Total debt | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Equity | MakklerPRO | MakklerPRO | MakklerPRO |
| LTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash from Operations | -$88.32M | $262.29M | -$48.56M |
| Capital expenditure | MakklerPRO | MakklerPRO | MakklerPRO |
| Free cash flow | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Investing | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Financing | MakklerPRO | MakklerPRO | MakklerPRO |
Standardised statements compiled from the company's annual and interim reports. The "LTM" column covers the last four reported quarters; balance-sheet lines in it are from the latest quarter. Lines the company does not report are left blank rather than approximated. Not investment advice.